7.7.5. current status predictive biomarkers. important advance recent years recognition alterations fgfr3 including mutations gene fusions predictive marker response fgfr inhibitors . recommended screen muc patients ideally diagnosis metastatic disease fgfr3 alterations plan optimal treatment including trials. many efforts focused markers predicting response immune checkpoint inhibition. programmed death-ligand 1 expression immunohistochemistry evaluated many studies mixed and, far, inconclusive results. may part related use different antibodies various scoring systems evaluating different compartments i.e., tumour cells, immune cells, both. major limitation pd-l1 staining relates significant proportion pd-l1-negative patients respond immune checkpoint blockade. predictive value pd-l1 confirmed large phase iii trials evaluating integration immunotherapy first-line setting muc [514-516]. present, indication pd-l1 testing muc dictated current ema approvals relates potential use immune checkpoint inhibitors first-line monotherapy patients unfit cisplatin-containing chemotherapy. another biomarker evaluated predicting response immunotherapy high tmb . neoantigen burden tmb associated response immune checkpoint blockade several malignancies. high tmb associated response immune checkpoint inhibitors metastatic uc small single-arm trials confirmed far rcts. markers evaluated predicting response immune checkpoint inhibitors include molecular subtypes, cd8 expression immunohistochemistry immune gene cell signatures. recent work focused importance stroma including role tgfs predicting response immune checkpoint blockade . conclusion, apart fgfr3 alterations, currently validated predictive molecular markers routinely used clinical practice.